On Monday, Syros Pharmaceuticals Inc (NASDAQ: SYRS) opened lower -7.14% from the last session, before settling in for the closing price of $0.09. Price fluctuations for SYRS have ranged from $0.07 to $6.93 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 161.81%. Company’s average yearly earnings per share was noted 74.11% at the time writing. With a float of $23.67 million, this company’s outstanding shares have now reached $26.83 million.
Considering the fact that the conglomerate employs 68 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is -228.76%, operating margin of -28892.23%, and the pretax margin is -25340.67%.
Syros Pharmaceuticals Inc (SYRS) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Syros Pharmaceuticals Inc is 11.80%, while institutional ownership is 8.27%. The most recent insider transaction that took place on Mar 14 ’25, was worth 924. Before that another transaction happened on Mar 11 ’25, when Company’s Director proposed sale 9,333 for $0.22, making the entire transaction worth $2,008.
Syros Pharmaceuticals Inc (SYRS) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 74.11% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 52.99% during the next five years compared to 21.16% growth over the previous five years of trading.
Syros Pharmaceuticals Inc (NASDAQ: SYRS) Trading Performance Indicators
Check out the current performance indicators for Syros Pharmaceuticals Inc (SYRS). In the past quarter, the stock posted a quick ratio of 2.25. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.90.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.03, a number that is poised to hit -0.65 in the next quarter and is forecasted to reach -0.95 in one year’s time.
Technical Analysis of Syros Pharmaceuticals Inc (SYRS)
Compared to the last year’s volume of 19.66 million, its volume of 163.87 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 7.83%. Additionally, its Average True Range was 0.04.
During the past 100 days, Syros Pharmaceuticals Inc’s (SYRS) raw stochastic average was set at 0.61%, which indicates a significant decrease from 8.85% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 364.24% in the past 14 days, which was lower than the 371.38% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.1704, while its 200-day Moving Average is $2.1709. Nevertheless, the first resistance level for the watch stands at $0.0953 in the near term. At $0.1048, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.1098. If the price goes on to break the first support level at $0.0808, it is likely to go to the next support level at $0.0758. Now, if the price goes above the second support level, the third support stands at $0.0663.
Syros Pharmaceuticals Inc (NASDAQ: SYRS) Key Stats
There are currently 26,832K shares outstanding in the company with a market cap of 2.30 million. Presently, the company’s annual sales total 9,940 K according to its annual income of -164,570 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -6,400 K.
